510709-83-8

Basic information

• Product Name: N-(5-Aminopentyl)maleimide hydrochloride salt
• Synonyms: N-(5-Aminopentyl)maleimide hydrochloride salt;1-(5-aMinopentyl)-1H-pyrrole-2,5-dione hydrochloride;N-(5-AMinopentyl)MaleiMide hydrochloride
• CAS NO: 510709-83-8
• Molecular Formula: C9H14N2O2.ClH
• Molecular Weight: 218.682
• Mol File: 510709-83-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(5-Aminopentyl)maleimide hydrochloride salt(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-Aminopentyl)maleimide hydrochloride salt(510709-83-8)
• EPA Substance Registry System: N-(5-Aminopentyl)maleimide hydrochloride salt(510709-83-8)

Safety Data

• Hazardous Substances Data: 510709-83-8(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
N-(5-Aminopentyl)maleimide hydrochloride salt is used as a crosslinking reagent for bioconjugation, allowing for the stable attachment of proteins or other biomolecules through the formation of thioether bonds with thiol groups.
Used in Protein Labeling:
In protein labeling applications, N-(5-Aminopentyl)maleimide hydrochloride salt serves as a labeling agent, enabling the covalent attachment of detection tags or other molecules to proteins, which can be crucial for tracking protein localization, interactions, or activity within biological systems.
Used in Site-Specific Protein Modification:
N-(5-Aminopentyl)maleimide hydrochloride salt is used as a modifier in site-specific protein engineering, where the introduction of specific chemical groups or the alteration of protein function is required for research or biotechnological purposes.
Used in Immobilization of Proteins:
N-(5-Aminopentyl)maleimide hydrochloride salt is utilized for the immobilization of proteins on various surfaces, which is essential for applications such as biosensors, diagnostics, and biocompatible materials in medical devices.
Used in Research and Biotechnology:
In the fields of research and biotechnology, N-(5-Aminopentyl)maleimide hydrochloride salt is employed for the study and manipulation of proteins, contributing to advancements in understanding protein structure, function, and interactions.

Upstream product

• 192212-24-1 tert-butyl 5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentylcarbamate 
• 55750-53-3 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid 
• 60-32-2 6-aminohexanoic acid 

Relevant articles and documents

SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF

The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.

ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF

The invention provides rF1 antibody antibiotic conjugates and methods of using same.

QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to antibody-drug conjugates represented by Formula (I) Ab- (L-D)p, Ab is an antibody; p is 1-8; L-D is a chemical moiety represented by the following formula -Str-(Pep)-Sp-D; Str is a stretcher unit covalently attached to Ab; Pep is a linker; D is anti-tumor agent represented by the following formula wherein Rand Rare each independently Ct-C6alkyl, and Ris a non-hydrogen substituent; or Ris C1-C6alkyl, and Rand Rtogether with the N form a substituted C3-C7heterocycloalkyl ring; or R° is absent, and Rand Rtogether with the N form a substituted heteroaryl ring; Sp-D is a spacer moiety of fomula: This invention also relates to a method of treating cancer, use of antibody-drug conjugates of Formula (I) in therapy, and use of antibody-drug conjugates of Formula (I) in manufacturing a medicament for treating cancer. This invention also relates to method of preparing antibody-drug conjugates of Formula (I).

ANTIBODIES AND IMMUNOCONJUGATES

The invention provides immunoconjugates and methods of using the same.

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging

Prostate-specific membrane antigen (PSMA) has been identified as a diagnostic and therapeutic target for prostate cancer. (S)-2-[3-[(R)-1-Carboxy- 2-mercaptoethyl]ureido-pentanedioic acid (Cys-CO-Glu) were used to design novel PSMA targeting probes by nucleophilic conjugate addition between cysteine and maleimide based reagents. 3 ([123I]IGLCE) was synthesized by this strategy and showed high affinity for PSMA. Results of binding inhibition assays of these derivatives suggested the importance of an aromatic group and succinimide moiety for high affinity. [123I]3 was evaluated in vivo with PSMA positive LNCaP and PSMA negative PC-3 human prostate cancer xenograft bearing mice. [125I]3 accumulated in LNCaP tumors but not in PC-3 tumors, and the accumulation was inhibited by 2-(phosphonomethyl)pentanedioic acid (2-PMPA). Use of [123I]3 provided positive images of LNCaP tumors in single photon emission tomography scans. These results warrant further evaluation of [123I]3 and its derivatives as radiolabeled probes for the diagnosis of prostate cancer.